A practical reference on pentapeptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Purity assessment for this peptide relies mainly on reversed-phase high-performance liquid chromatography. A C18 column with a water-acetonitrile gradient containing trifluoroacetic acid separates the target from truncated sequences and oxidation products. Detection near 214 nm exploits the amide backbone, while the aromatic side chains allow additional monitoring close to 280 nm. Reported purity values depend on the method, so a certificate of analysis carries weight only when gradient, column and integration parameters are given.
Mass spectrometry confirms identity and reveals structural deviations that chromatography alone can miss. Positive-mode electrospray ionisation generally yields multiply charged ions whose deconvoluted mass is checked against the theoretical value. Amino acid analysis, and enzymatic digestion with subsequent fragment mapping, provide independent confirmation of sequence and of the terminal amide. Analysts take care to separate the target from deletion sequences, which may differ by one residue and therefore by only a small mass increment.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class. It acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. The compound was designed in the 1990s during a search for agents that release growth hormone with fewer off-target hormonal effects than earlier secretagogues. It appears in the research literature under several sequence-based names. Material supplied for laboratory work is normally a lyophilized solid, and it is not marketed as an approved therapeutic in major jurisdictions.
The molecule contains five residues, including alpha-aminoisobutyric acid, D-2-naphthylalanine, and D-phenylalanine, and it ends in a lysine amide. Non-natural and D-configured residues make the chain less susceptible to common peptidases, which helps explain its resistance to rapid breakdown. Its molecular formula is C38H49N9O5, corresponding to a free-base mass near 711.9 daltons. The C-terminal amide removes a negative charge and is a recurring feature in receptor-active peptides of this family. These structural choices are usually discussed as the basis for its selectivity profile.
| Property | Value | Notes |
|---|---|---|
| Primary purity method | Reversed-phase HPLC | C18 column, water-acetonitrile gradient |
| Detection wavelength | 214 nm, optionally 280 nm | Amide backbone and aromatic side chains |
| Identity confirmation | Electrospray ionisation mass spectrometry | Deconvoluted mass compared with theory |
| Storage of solid | -20 °C or lower, dry and dark | Stability depends on residual moisture |
| Storage in solution | 2-8 °C, short term | Freeze-thaw cycling avoided |
Analytical confirmation relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry for identity and purity assessment. Mass spectrometry distinguishes the intact molecule from truncation products and from oxidation or deamidation variants that share similar chromatographic retention. Immunoassays appear in some biological studies but can cross-react with related peptides, so they are weaker tools for identity work. Reported purity figures depend heavily on the gradient, detector, and integration method used, which complicates direct comparison between laboratories.
Research quantities of ipamorelin are typically distributed as a white to off-white lyophilized powder. The solid dissolves readily in water and in aqueous buffers, and stock solutions are commonly prepared in sterile water or a mildly acidic diluent. Adsorption to plastic and glass surfaces can reduce the concentration of very dilute solutions, so containers and transfer steps deserve attention when accurate concentrations matter. Reconstituted material is generally used promptly rather than held for extended periods.
Storage recommendations for the dry solid center on low temperature and low moisture, most often -20 °C in a sealed, desiccated container protected from light. Solutions are less stable than the powder and are usually kept cold and used within a short window. Freeze-thaw cycling is a recognized source of loss, and aliquoting before freezing is a standard precaution. These practices derive from general peptide handling principles rather than from a single published stability trial, so exact shelf lives should be treated as approximate.
=== 13 April === The Ukrainian Defence Ministry confirmed that Russian forces had reached the northern outskirts of Bohdanivka, ten kilometers from Chasiv Yar. Russia claimed to have taken Pervomaiske, 11 kilometers west of Avdiivka. Three people were killed in separate Russian attacks in Donetsk Oblast, while two people were killed in Kharkiv Oblast. One person was killed in a Russian attack on a car carrying humanitarian aid in Chernihiv Oblast. The Russian-installed head of Luhansk Oblast claimed that three people were injured in a Ukrainian missile attack on a factory in Luhansk city. Ukrainian officials claimed to have destroyed a major Russian headquarters using Storm Shadow missiles. Russian media later reported that Colonel Pavel Kropotov, commander of the 59th Guards Communications Brigade, was killed in the attack. The SBU announced that it had thwarted an assassination attempt against Kherson Oblast Governor Oleksandr Prokudin, adding that it had arrested a suspect who tried to launch a drone at his car. The IAEA reported that the Zaporizhzhia Nuclear Power Plant had been placed in a state of cold shutdown for the first time since October 2022. Germany announced that it would deliver another Patriot battery and additional missiles to Ukraine.
=== Cancer treatment === Pardaxin inhibits proliferation and induces apoptosis of human cancer cell lines. Its 33-amino acid structure contains many cationic and amphipathic amino acids. This makes it easier for it to interact with anionic membranes, such as those in tumor cells, which are inherently more acidic because of the acidic environment created by more glycolysis. Pardaxin initiates caspase-dependent and caspase-independent apoptosis in human cervical carcinoma cells. Pardaxin triggers reactive oxygen species (ROS). ROS production disrupts protein folding and induces the unfolded protein response (UPR). This causes stress on the endoplasmic reticulum, which releases calcium. This leads to an increase in mitochondrial calcium, dropping its membrane potential. The pore permeability changes, and Cytochrome c (Cyt c) is released. Cyt c activates the caspase chain that leads to apoptosis. ROS also activates the JNK pathway. JNK is phosphorylated, which leads to the phosphorylation of AP-1 (transcription factor consisting of cFOS and Cjun). This results in the activation of caspases as well. ROS also causes a caspase independent pathway that results in apoptosis. When the mitochondrial membrane potential changes, apoptosis-inducing factors (AIFs) are also released. These trigger apoptosis when they enter the nucleus, not needing to involve caspases.
=== Pharmacodynamics === Similarly to ketamine, norketamine acts as a noncompetitive NMDA receptor antagonist (Ki = 1.7 μM and 13 μM for (S)-(+)-norketamine and (R)-(–)-norketamine, respectively). Also, similarly again to ketamine, norketamine binds to the μ- and κ-opioid receptors. Relative to ketamine, norketamine is much more potent as an antagonist of the α7-nicotinic acetylcholine receptor, and produces rapid antidepressant effects in animal models which have been reported to correlate with its activity at this receptor. However, norketamine is about 1/5 as potent as ketamine as an antidepressant in mice as per the forced swim test, and this seems also to be in accordance with its 3–5-fold reduced comparative potency in vivo as an NMDA receptor antagonist. Norketamine's metabolites, dehydronorketamine (DHNK) and hydroxynorketamine (HNK), are far less or negligibly active as NMDA receptor antagonists in comparison, but retain activity as potent antagonists of the α7-nicotinic acetylcholine receptor. In 2024, norketamine was discovered to act as a highly potent positive allosteric modulator of the opioid receptors, including of the μ-opioid receptor (MOR). It shares this action with ketamine and hydroxynorketamine (HNK). They are all active in this action at very low concentrations, for instance 1 nM. Ketamine, norketamine, and HNK can potentiate the effects of endogenous opioids like met-enkephalin and exogenous opioids like morphine.
== Characteristics of drugs candidate to therapeutic drug monitoring == In pharmacotherapy, many medications are used without monitoring of blood levels, as their dosage can generally be varied according to the clinical response that a patient gets to that substance. For certain drugs, this is impracticable, while insufficient levels will lead to undertreatment or resistance, and excessive levels can lead to toxicity and tissue damage. Indications in favor of therapeutic drug monitoring include:
Sources: en.wikipedia.org
A moderate degree of iron-deficiency anemia affects approximately 610 million people worldwide or 8.8% of the population. It is slightly more common in females (9.9%) than males (7.8%). Up to 15% of children ages 1–3 years have iron deficiency anemia. Mild iron deficiency anemia affects another 375 million. Iron deficiency affects up to 52% of pregnant women worldwide. The prevalence of iron deficiency as a cause of anemia varies among countries; in the groups in which anemia is most common, including young children and a subset of non-pregnant women, iron deficiency accounts for a fraction of anemia cases in these groups (25% and 37%, respectively). Iron deficiency is common in pregnant women. Within the United States, iron-deficiency anemia affects about 2% of adult males, 10.5% of White women, and 20% of African-American and Mexican-American women. A study in 2024 suggests that nearly 1 in 3 Americans may have undiagnosed iron deficiency, which can cause fatigue, brain fog, and concentration problems. The analysis of data from over 8,000 U.S. adults found that 14% had low iron levels, known as absolute iron deficiency; 15% had normal iron levels but their bodies couldn't effectively use the mineral, a condition called functional iron deficiency. A map provides a country-by-country listing of what nutrients are fortified into specified foods. Some of the Sub-Saharan countries shown in the deaths from iron-deficiency anemia map from 2012 are, as of 2018, fortifying foods with iron.
==== Proposed joint US-USSR program ==== After a first US-USSR Dryden-Blagonravov agreement and cooperation on the Echo II balloon satellite in 1962, President Kennedy proposed on September 20, 1963, in a speech before the United Nations General Assembly, that the United States and the Soviet Union join forces in an effort to reach the Moon. Kennedy thus changed his mind regarding the desirability of the space race, preferring instead to ease tensions with the Soviet Union by cooperating on projects such as a joint lunar landing. Soviet Premier Nikita Khrushchev initially rejected Kennedy's proposal. However, on October 2, 1997, it was reported that Khrushchev's son Sergei claimed Khrushchev was poised to accept Kennedy's proposal at the time of Kennedy's assassination on November 22, 1963. During the next few weeks he reportedly concluded that both nations might realize cost benefits and technological gains from a joint venture, and decided to accept Kennedy's offer based on a measure of rapport during their years as leaders of the world's two superpowers, but changed his mind and dropped the idea since he lacked the same trust for Kennedy's successor, Lyndon Johnson. Some cooperation in robotic space exploration nevertheless did take place, such as a combined Venera 4–Mariner 5 data analysis under a joint Soviet–American working group of COSPAR in 1969, allowing a more complete drawing of the profile of the atmosphere of Venus. Eventually the Apollo–Soyuz mission was realized afterall, which furthermore laid the foundations for the Shuttle-Mir program and the ISS.
== Bibliography == Hall, John (2011). Guyton and Hall Textbook of Medical Physiology (12th ed.). Philadelphia: Saunders/Elsevier. ISBN 978-1-4160-4574-8. Longo, Dan; Fauci, Anthony; Kasper, Dennis; Hauser, Stephen; Jameson, J.; Loscalzo, Joseph (2011). Harrison's Principles of Internal Medicine (18th ed.). McGraw-Hill Professional. ISBN 978-0-07-174889-6. Susan Standring; Neil R. Borley; et al., eds. (2008). Gray's anatomy: the anatomical basis of clinical practice (40th ed.). London: Churchill Livingstone. ISBN 978-0-8089-2371-8. Nicki R. Colledge; Brian R. Walker; Stuart H. Ralston, eds. (2010). Davidson's principles and practice of medicine (21st ed.). Edinburgh: Churchill Livingstone/Elsevier. ISBN 978-0-7020-3085-7.
As early as 1971, Kardashev considered that this observation requires the preparation of a plan of listening and analysis, which will allow the success of the search for extraterrestrial civilizations. Humanity will then be able to solve the "main dilemma", as it was stated by Enrico Fermi. This dilemma is, according to the Soviet astronomer, is certainly connected with our lack of information and knowledge. Kardashev believes that a research project like Ozma is incapable of detecting a Type I civilization (an idea also promoted by Kaplan in 1971), and that SETI should instead focus on searching for intense radio signals that could emanate from active Type II or III civilizations. To prove the effectiveness of this approach, Kardashev therefore turned his attention to two radio sources discovered by the California Institute of Technology, nicknamed CTA-21 and CTA-102. Subsequently, Gennadii Borisovich Sholomitskii then used the Russian astronomical research station to study the data from CTA-102. He found that this radio source is characterized by its variability. Kardashev then considered that this could be an indication of an artificial emission source, albeit of rather short life span.
In the 17th century the Italian Marcello Malpighi used microscopes to study tiny biological entities; some regard him as the founder of the fields of histology and microscopic pathology. Malpighi analyzed several parts of the organs of bats, frogs and other animals under the microscope. While studying the structure of the lung, Malpighi noticed its membranous alveoli and the hair-like connections between veins and arteries, which he named capillaries. His discovery established how the oxygen breathed in enters the blood stream and serves the body. In the 19th century histology was an academic discipline in its own right. The French anatomist Xavier Bichat introduced the concept of tissue in anatomy in 1801, and the term "histology" (German: Histologie), coined to denote the "study of tissues", first appeared in a book by Karl Mayer in 1819. Bichat described twenty-one human tissues, which can be subsumed under the four categories currently accepted by histologists. The usage of illustrations in histology, deemed as useless by Bichat, was promoted by Jean Cruveilhier. In the early 1830s Purkynĕ invented a microtome with high precision. During the 19th century many fixation techniques were developed by Adolph Hannover (solutions of chromates and chromic acid), Franz Schulze and Max Schultze (osmic acid), Alexander Butlerov (formaldehyde) and Benedikt Stilling (freezing).
Sources: en.wikipedia.org
Results are most often expressed as a percentage of total peak area from a reversed-phase separation. That figure reflects the detection wavelength, gradient and integration choices used by the laboratory. Two valid certificates can therefore quote different values for the same material without either being incorrect.
Chromatography separates components but does not identify them. Mass measurement gives an independent check that the main peak corresponds to the expected molecular mass. Used together, the two techniques detect both impurity load and structural misassignment.
Hydrolysis and oxidation are the main degradation routes in aqueous media. Loss of the C-terminal amide and oxidation of the aromatic residues are commonly reported changes. Cool storage and short working periods limit the extent of both processes.
It has not been approved as a therapeutic by major regulators, and the human trial record is small and dated. Material available today is mostly sold as a research chemical for laboratory use. Approval and restriction status varies by country.